205 related articles for article (PubMed ID: 6129576)
21. [Therapeutic experience with ulcerative colitis and Crohn disease].
Nagy G; Prónay G; Ujszászy L
Orv Hetil; 1985 Jan; 126(1):17-20, 23-4. PubMed ID: 2857480
[No Abstract] [Full Text] [Related]
22. Sulfasalazine therapy in inflammatory bowel disease.
Das KM
Gastroenterol Clin North Am; 1989 Mar; 18(1):1-20. PubMed ID: 2563989
[TBL] [Abstract][Full Text] [Related]
23. [Drug treatment of chronic inflammatory diseases of the intestine].
Modigliani R
Schweiz Med Wochenschr; 1988 May; 118(20):737. PubMed ID: 2898809
[No Abstract] [Full Text] [Related]
24. [Side effects of salicylazosulfapyridine therapy].
Miller B
Dtsch Med Wochenschr; 1980 Nov; 105(46):1596-7. PubMed ID: 6108200
[No Abstract] [Full Text] [Related]
25. Desensitization of patients with inflammatory bowel disease to sulfasalazine.
Taffet SL; Das KM
Am J Med; 1982 Oct; 73(4):520-4. PubMed ID: 6127032
[TBL] [Abstract][Full Text] [Related]
26. [Salazosulfapyridine-induced lupus erythematosus syndrome in ulcerative colitis (author's transl)].
Jaup BH
Dtsch Med Wochenschr; 1978 Jul; 103(30):1211-3. PubMed ID: 27347
[TBL] [Abstract][Full Text] [Related]
27. Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?
Fischer C; Klotz U
Ther Drug Monit; 1980; 2(2):153-8. PubMed ID: 6132473
[No Abstract] [Full Text] [Related]
28. Medical treatment of ulcerative colitis and Crohn's disease.
Rhodes JM
J Clin Hosp Pharm; 1983 Sep; 8(3):219-32. PubMed ID: 6138368
[No Abstract] [Full Text] [Related]
29. [New developments and trends in the drug therapy of chronic inflammatory bowel diseases].
Ewe K
Verh Dtsch Ges Inn Med; 1988; 94():178-84. PubMed ID: 2905098
[No Abstract] [Full Text] [Related]
30. The immunology of inflammatory bowel disease.
MacKechnie HL
Henry Ford Hosp Med J; 1982; 30(1):25-32. PubMed ID: 6123493
[No Abstract] [Full Text] [Related]
31. Pharmacotherapy of inflammatory bowel disease.
Gardner RC
J Maine Med Assoc; 1976 Jul; 67(7):206-14. PubMed ID: 9461
[No Abstract] [Full Text] [Related]
32. Investigations on the absorption of azulfidine.
Müller-Wieland K; Berndt W; Hirt O
Am J Proctol; 1970 Oct; 21(5):337-40. PubMed ID: 4394894
[No Abstract] [Full Text] [Related]
33. Proceedings: Effects of sulphasalazine (Salazopyrin) on faecal flora in patients with inflammatory bowel disease.
Lendrum R; Walker JG; West B; Hill MJ
Gut; 1974 Apr; 15(4):344. PubMed ID: 4151868
[No Abstract] [Full Text] [Related]
34. Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy.
Gorbach SL; Nahas L; Plaut AG; Weinstein L; Patterson JF; Levitan R
Gastroenterology; 1968 Apr; 54(4):575-87. PubMed ID: 4385122
[No Abstract] [Full Text] [Related]
35. [Salazosulfapyridine in pregnancy?].
Fahrländer H
Dtsch Med Wochenschr; 1980 Dec; 105(50):1729-31. PubMed ID: 6108202
[No Abstract] [Full Text] [Related]
36. [Chronic inflammatory intestinal disease and pregnancy].
Damgaard B; Orholm M
Ugeskr Laeger; 1984 Jun; 146(23):1701-4. PubMed ID: 6150567
[No Abstract] [Full Text] [Related]
37. [Immunomodulation treatment of inflammatory bowel disease].
Stave R
Tidsskr Nor Laegeforen; 1984 Jan; 104(3):153-4. PubMed ID: 6142543
[No Abstract] [Full Text] [Related]
38. [Depression induced by salazosulfapyridine in cyclothymia and Crohn disease].
Scherer J
Nervenarzt; 1988 Jun; 59(6):371-3. PubMed ID: 2901048
[No Abstract] [Full Text] [Related]
39. [Hypersensitivity reaction to sulfasalazine with a clinical picture similar to mononucleosis].
Foresti V; Tronci M; Ungaro A; Confalonieri F
Recenti Prog Med; 1988 Sep; 79(9):382-3. PubMed ID: 2904684
[No Abstract] [Full Text] [Related]
40. Drug management of inflammatory bowel disease.
McCarthy CF
Ir Med J; 1983 May; 76(5):260-2. PubMed ID: 6135675
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
